Evolent Health (EVH) Stock Price, News & Analysis

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evolent Health in the last year. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" EVH shares.
View EVH analyst ratings or view top-rated stocks.

11 Wall Street research analysts have issued 1 year target prices for Evolent Health's shares. Their EVH share price targets range from $34.00 to $52.00. On average, they expect the company's stock price to reach $43.00 in the next twelve months. This suggests a possible upside of 45.0% from the stock's current price.
View analysts price targets for EVH or view top-rated stocks among Wall Street analysts.

Evolent Health's stock was trading at $33.03 at the start of the year. Since then, EVH shares have decreased by 10.2% and is now trading at $29.65.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our EVH earnings forecast.

Evolent Health, Inc. (NYSE:EVH) posted its earnings results on Thursday, February, 22nd. The technology company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.13. The technology company had revenue of $556.06 million for the quarter, compared to the consensus estimate of $541.87 million. Evolent Health had a negative net margin of 5.76% and a positive trailing twelve-month return on equity of 6.60%.

ETFs with the largest weight of Evolent Health (NYSE:EVH) stock in their portfolio include Fidelity Digital Health ETF (FDHT), Harbor Corporate Culture Small Cap ETF (HAPS) and Fidelity Disruptive Medicine ETF (FMED).Harbor Small Cap Explorer ETF (QWST).

Evolent Health updated its FY 2024 earnings guidance on Thursday, February, 22nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $2.4 billion-$2.5 billion, compared to the consensus revenue estimate of $2.3 billion.

12 employees have rated Evolent Health Chief Executive Officer Seth Blackley on Glassdoor.com. Seth Blackley has an approval rating of 100% among the company's employees. This puts Seth Blackley in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Evolent Health investors own include Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Universal Insurance (UVE), Endologix (ELGX), Advanced Micro Devices (AMD), Energy Transfer (ET), Chipotle Mexican Grill (CMG), Ford Motor (F), Cisco Systems (CSCO) and Heron Therapeutics (HRTX).

Evolent Health (EVH) raised $150 million in an initial public offering (IPO) on Friday, June 5th 2015. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Goldman Sachs served as the underwriters for the IPO and Wells Fargo Securities, William Blair, SunTrust Robinson Humphrey and Leerink Partners were co-managers.

Evolent Health's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Hodges Capital Management Inc. (0.41%), Salem Investment Counselors Inc. (0.10%), ERn Financial LLC (0.05%), WoodTrust Financial Corp (0.04%), First Dallas Securities Inc. (0.01%) and Banque Cantonale Vaudoise (0.00%). Insiders that own company stock include Cheryl Scott, Daniel Joseph Mccarthy, Diane Holder, Frank J Williams, Frank J Williams, John Paul Johnson, Jonathan Weinberg, Mary Bridget Duffy, Seth Blackley, Simon Maisey and Steve Tutewohl.
View institutional ownership trends.

Shares of EVH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.